Compare BBCP & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | FENC |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.8M | 430.3M |
| IPO Year | 2017 | 2010 |
| Metric | BBCP | FENC |
|---|---|---|
| Price | $9.01 | $12.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.25 | ★ $14.50 |
| AVG Volume (30 Days) | 127.0K | ★ 237.0K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $392,867,000.00 | $44,642,000.00 |
| Revenue This Year | $4.90 | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $205.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $5.65 |
| 52 Week High | $12.19 | $13.25 |
| Indicator | BBCP | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 57.26 |
| Support Level | $8.89 | $9.74 |
| Resistance Level | $12.08 | N/A |
| Average True Range (ATR) | 0.33 | 0.57 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 28.99 | 64.54 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.